PEARL-III: 12 weeks of ABT-450/R/267 + ABT-333 achieved SVR in >99% of 419 treatment-naive HCV genotype 1B-infected adults with or without ribavirin

Authors
Category Primary study
JournalJournal of Hepatology
Year 2014
This article has no abstract
Epistemonikos ID: e3181fc7c59dfed5edaefcd7a42d65a37d347515
First added on: Feb 06, 2025